On 18 November 2025, genomic‑diagnostics firm MedGenome filed its Draft Red‑Herring Prospectus (DRHP) for an IPO of up to ₹500 crore. The company specialises in rare‑disease genomics and has a recurring revenue model servicing hospitals, research institutes and biopharma clients across India and Southeast Asia. Analysts said the issue could attract attention from healthcare‑tech funds given the niche focus, while broader market conditions remain cautious. The company plans to expand its sequencing‑capacity and launch new precision‑medicine services after listing.